Hyperion Therapeutics shares are surging today following news that its drug RAVICTI was approved by the Food and Drug Administration for the treatment of a rare disease called urea cycle disorder. While RAVICTI isn't the first drug to treat the disease, its convenience is head and shoulders above the existing option. Follow along in the video below as health care bureau chief Brenton Flynn discusses the news and what's next for Hyperion now that RAVICTI is approved.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Hyperion Surges on FDA Approval, but What's Next? originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.